3C PATCH® REIMBURSEMENT

3C Patch® System is an FDA-cleared advanced wound management solution.
Nationally covered by Medicare, read the press release here.

Medicare Code – G0460
ICD 10 – Two diagnosis codes are required – Diabetic Mellitus plus Chronic Ulcer
National Average Payment – $1,715.36
Nurse inputting data into a computer

Our reimbursement specialists are available to provide support and answer any questions you might have about coding, billing, and reimbursement. Give us a call or send us an email and we will be happy to assist you.

FOR MORE INFORMATION AND PRODUCT PRICING

Scientific and clinical data support the effect of 3C Patch® in wound management, compared to standard of care.

The results of a multinational, multicentre randomized clinical trial published in Lancet Diabetes & Endocrinology 2018 served as the basis for CMS reimbursement.
The International Working Group on Diabetic Foot recommends 3C Patch® as adjunctive therapy for hard-to-heal diabetic foot ulcers.

Effective April 13, 2021, Medicare covers the 3C Patch for the treatment of chronic non-healing diabetic wounds for 20 weeks.

The 3C Patch® System is a single use medical device used to prepare an autologous platelet-rich plasma (PRP) gel from the patient’s peripheral blood by centrifugation, without any reagents.  Under the supervision of a healthcare professional, the PRP gel produced by the 3C Patch® System is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, and diabetic ulcers and mechanically or surgically-debrided wounds.  See 510(k) Summary – BK200471 (accessed Sept. 17, 2021), available at https://www.fda.gov/media/104546/download.

See Medicare Claims Processing Manual, CMS Pub. 100-04: Transmittal 11119, National Coverage Determination
(NCD) 270.3 Blood-Derived Products for Chronic, Non-Healing Wounds (November 10, 2021), available at https://www.cms.gov/files/document/r11119cp.pdf

FDA CLEARANCE

The 3C Patch® System is cleared by the FDA for the management of exuding wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically debrided wounds.

CE MARKED IN EUROPE

The intended use of the 3C Patch® Device is to produce an autologous platelet-rich fibrin patch for wound management of recalcitrant wounds.